Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vernakalant versus amiodarone for recent-onset atrial fibrillation
2007-005625-29Phase 3Completed
- Sponsor
- Correvio Pharma Corp.
- Start
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Atrial fibrillation (AFib) comparing Vernakalant injection with Amiodarone injection (2 arms). Primary endpoint: Conversion of atrial fibrillation to sinus rhythm within 90 minutes. Started Jan 2008; status: completed.
02
Drugs
vernakalantamiodarone
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2007-005625-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005625-29.